Other News To Note
Wednesday, December 21, 2011
Apeiron Biologics AG, of Vienna, Australia, said GlaxoSmithKline plc, of London, exclusive, worldwide licensee for Apeiron's new investigational recombinant human Angiotensin Converting Enzyme 2 (GSK2586881, formerly APN01), has initiated a Phase IIa study in patients suffering from acute lung injury.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.